Evidence map›Paper›PMID 38588407›Full record

ArticleCancer research2024

Integrin αvβ3 Upregulation in Response to Nutrient Stress Promotes Lung Cancer Cell Metabolic Plasticity.

Arin Nam, Shashi Jain, Chengsheng Wu, Alejandro Campos, Ryan M Shepard, Ziqi Yu, Joshua P Reddy, Tami Von Schalscha, Sara M Weis, Mark Onaitis and 2 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Arin Nam *Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0003-1253-6120
Shashi Jain *Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0001-9428-0135
Chengsheng WuDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0003-3091-1606
Alejandro CamposDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0002-1645-4862
Ryan M ShepardDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0002-7488-369X
Ziqi YuDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0002-4952-8899
Joshua P ReddyDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0005-7211-0641
Tami Von SchalschaDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0007-8348-6200
Sara M WeisDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0008-3137-4239
Mark OnaitisDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0003-0997-6563
Hiromi I WetterstenDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0001-7144-3122
David A ChereshDepartment of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0002-7193-8595

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
REGULATION OF TUMOR CELL ATTACHMENT BY SURFACE ANTIGENSR01CA045726 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERESH, DAVID A · 1988 to 2017
$7.4M
Attacking stress tolerance in cancerR35CA220512 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERESH, DAVID A · 2018 to 2024
$6.5M
αvβ3-induced epithelial cancer progression via macrophage recruitmentK01OD030513 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WETTERSTEN, HIROMI INOUE · 2021 to 2025
$647k
California Institute for Regenerative Medicine (CIRM) FA1-00607National Cancer Institute (NCI) P30CA23100National Cancer Institute (NCI) R01CA045726National Cancer Institute (NCI) R35CA220512National Institute of General Medical Sciences (NIGMS) T32GM007752National Institute of Neurological Disorders and Stroke (NINDS) P30NS047101NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA045726NCI NIH HHS R35 CA220512NCI NIH HHS T32 CA121938NIGMS NIH HHS T32 GM007752NIH HHS K01 OD030513NINDS NIH HHS P30 NS047101Office of Research Infrastructure Programs (ORIP) K01OD030513San Diego Digestive Diseases Research Center, School of Medicine, University of California, San Diego (SDDRC) DD2204Tobacco-Related Disease Research Program (TRDRP) T29FT0343Tobacco-Related Disease Research Program (TRDRP) T30FT083C
6 · The paper itself

Abstract

Cancer stem/tumor-initiating cells display stress tolerance and metabolic flexibility to survive in a harsh environment with limited nutrient and oxygen availability. The molecular mechanisms underlying this phenomenon could provide targets to prevent metabolic adaptation and halt cancer progression. Here, we showed in cultured cells and live human surgical biopsies of non-small cell lung cancer that nutrient stress drives the expression of the epithelial cancer stem cell marker integrin αvβ3 via upregulation of the β3 subunit, resulting in a metabolic reprogramming cascade that allows tumor cells to thrive despite a nutrient-limiting environment. Although nutrient deprivation is known to promote acute, yet transient, activation of the stress sensor AMP-activated protein kinase (AMPK), stress-induced αvβ3 expression via Src activation unexpectedly led to secondary and sustained AMPK activation. This resulted in the nuclear localization of peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC1α) and upregulation of glutamine metabolism, the tricarboxylic acid cycle, and oxidative phosphorylation. Pharmacological or genetic targeting of this axis prevented lung cancer cells from evading the effects of nutrient stress, thereby blocking tumor initiation in mice following orthotopic implantation of lung cancer cells. These findings reveal a molecular pathway driven by nutrient stress that results in cancer stem cell reprogramming to promote metabolic flexibility and tumor initiation. SIGNIFICANCE: Upregulation of integrin αvβ3, a cancer stem cell marker, in response to nutrient stress activates sustained AMPK/PGC1α signaling that induces metabolic reprogramming in lung cancer cells to support their survival. See related commentary by Rainero, p. 1543.

Indexed as

Carcinoma, Non-Small-Cell LungIntegrin alphaVbeta3Lung NeoplasmsUp-RegulationAMP-Activated Protein KinasesAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceNeoplastic Stem CellsNutrientsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaStress, PhysiologicalAMP-Activated Protein KinasesIntegrin alphaVbeta3NutrientsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha

Identifiers

PMID38588407
PMCPMC11096068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.